百济神州(06160.HK)卵巢癌新药上市申请获纳入优先审评
百济神州(06160.HK)公布,在研PARP1和PARP2抑制剂「帕米帕利」新药上市许可申请,获国家药品监督管理局药品审评中心纳入优先审评。
该产品主要用於治疗既往接受过至少两线化疗、携有致病或疑似致病的胚系BRCA突变的晚期卵巢癌、输卵管癌或原发性腹膜癌患者。百济神州肿瘤免疫学首席医学官贲勇表示,帕米帕利为集团第三款自主研发的创新药物,申请能迅速被纳入优先审评,表明目前此项晚期疾病的患者群体中尚存在未被满足的治疗需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.